HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $39 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Regenxbio (NASDAQ:RGNX) and maintained a price target of $39.
September 04, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Regenxbio and maintained a price target of $39, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $39 price target by HC Wainwright & Co. suggests a positive outlook for Regenxbio. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100